Certara, Inc.

CERT Net selling

CIK 0001827090 #2340 in the set updated 18 Sep 2026

Bought (120 mo)

$2.11M

out of their own pocket, the only kind of buying there is

Sold (120 mo)

$2.05B

$3.18M on a plan · $54.00K straight out of an exercise

Sold at will

$2.05B

131 of 149 sales

Net

−$2.05B

−$2.04B against sales at will

By person

30 insiders · 158 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

EQT Avatar Parent L.P.

10% owner

—

$1.93B (8)

−$1.93B

58,971,229

38.66%

$489.46M

−60.2%

SLAINE MASON P

Director

—

$50.85M (16)

−$50.85M

660,322

0.4329%

$5.48M

−75.8%

Feehery William F

CHIEF EXECUTIVE OFFICER

$200.00K (1)

$31.78M (26)

−$31.58M

2,360,769

1.55%

$19.59M

−26.7%

Schemick Michael Andrew

CHIEF FINANCIAL OFFICER

$416.00K (1)

$12.56M (10)

−$12.15M

522,895

0.3428%

$4.34M

−39.3%

Traynor Richard M.

SVP AND GENERAL COUNSEL

$5.64K (1)

$6.15M (27)

−$6.14M

173,524

0.1138%

$1.44M

—

Rayner Craig R.

PRESIDENT, INTEGRATED DRUG DEV

—

$4.78M (7)

−$4.78M

316,010

0.2072%

$2.62M

−30.6%

Pedersen Leif E

PRESIDENT, CHIEF COMMERCAL OFF

—

$4.45M (9)

−$4.45M

110,045

0.0721%

$913.37K

−57.0%

Aspbury Robert

PRESIDENT, PREDICTIVE TECH

—

$3.76M (10)

−$3.76M

332,442

0.2179%

$2.76M

−11.0%

Choe Jieun W.

CHIEF STRATEGY & MARKETING

—

$3.00M (10)

−$3.00M

248,577

0.1630%

$2.06M

−23.4%

Edge Justin

PRES., REGULATORY & ACCESS

—

$1.90M (10)

−$1.90M

394,764

0.2588%

$3.28M

−7.8%

SMITH PATRICK F

PRESIDENT, DRUG DEV SOLUTIONS

—

$1.28M (13) scheduled

−$1.28M

50,091

0.0328%

$415.76K

−49.8%

CASHMAN JAMES E III

Director

$460.00K (1)

$1.31M (2)

−$850.02K

484,197

0.3174%

$4.02M

—

McLean Stephen M.

Director

$832.40K (2)

—

+$832.40K

42,000

0.0275%

$348.60K

—

BROSHY ERAN

Director

$79.06K (2)

—

+$79.06K

50,708

0.0332%

$420.88K

—

WALSH MATTHEW M

Director

$115.00K (1)

$177.75K (1)

−$62.75K

213,316

0.1398%

$1.77M

—

McCoy Sherilyn S

Director

—

—

—

621,143

0.4072%

$5.16M

+1.1%

Dickinson Judith

See Remarks

—

—

—

173,564

0.1138%

$1.44M

+7.4%

Gallagher John E

Chief Financial Officer

—

—

—

95,371

0.0625%

$791.58K

—

Killefer Nancy

Director

—

—

—

51,846

0.0340%

$430.32K

—

Collins Cynthia

Director

—

—

—

51,846

0.0340%

$430.32K

—

Crane Rosemary A

Director

—

—

—

45,672

0.0299%

$379.08K

—

Resnick Jon Matthew

Chief Executive Officer

—

—

—

35,389

0.0232%

$293.73K

—

Corcoran Daniel

SVP and General Counsel

—

—

—

32,046

0.0210%

$265.98K

—

Reynders John V W

Chief Financial Officer

—

—

—

26,466

0.0174%

$219.67K

—

SHERMAN NICOLETTE D

CHIEF HUMAN RESOURCES OFFICER

—

—

—

24,358

0.0160%

$202.17K

—

Anhalt Rona

Chief Human Resources Officer

—

—

—

16,789

0.0110%

$139.35K

—

Virkler Drayton

PRESIDENT, REG & ACCES

—

—

—

12,415

0.0081%

$103.04K

—

McKemey Adrian

President, Drug Dev. Solutions

—

—

—

8,207

0.0054%

$68.12K

—

Gallagher Carol Giltner

Director

—

—

—

7,059

0.0046%

$58.59K

—

Bedi Arjun

Director

—

—

—

5,547

0.0036%

$46.04K

—

Individual transactions

0

Nothing of that kind in this period.

What was left out

Form 4 filings counted 235

Amendments (4/A) skipped 2

Filings about a different issuer 0

Unreadable filings 0

Joint filings 8

Sales on a Rule 10b5-1 plan 17

Sales straight out of an exercise 1

Sales at will 131

Transactions with no price 0

Shares from compensation/vesting 2,989,829

Sales filed before the plan box existed 131

History held since 16 Dec 2020